Daily closing price · 250 sessions
Quantitative price outlook based on available market signals. Not financial advice.
Indicators calculated from the stored daily price history.
A verified, data-driven analysis will be generated here from price action, technical indicators, fundamentals, earnings and market context.
Dedicated research sections for 2026, 2030, 2035, 2040 and 2050. Numerical targets will appear only after the long-horizon model is validated.
Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2026 research →Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2030 research →Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2035 research →Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2040 research →Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2050 research →Only stories explicitly associated with this stock are shown.
Centene Corporation reported Q2 2026 adjusted EPS of $2.51, marking a significant recovery from a loss a year prior, driven by improved medical cost trends and better execution. The company expects Medicaid membership to decline 8%-9% in 2026, but profitability improvements in Marketplace and Medicare segments, combined with higher Medicaid rates and cost initiatives, support continued recovery. CNC reaffirmed its 2026 adjusted EPS guidance above $4.80.
IQVIA (IQV) has surged 60.1% over six months, driven by 6% organic growth in Q2 2026, with R&DS bookings up 19.3% and a $34.2 billion backlog. The company's rapid AI adoption—294 agents deployed across 90 use cases with 19 of top 20 pharma companies adopting solutions—is strengthening its competitive position and supporting sustained growth.
The Invesco S&P 500 Pure Value ETF (RPV) is a smart beta ETF with $1.75 billion in assets that tracks the S&P 500 Pure Value Index. It has delivered 19.31% year-to-date returns and 26.47% over the past year with a 0.35% expense ratio. The fund holds 125 stocks with heavy exposure to Financials (20.4%), Healthcare, and Consumer Staples sectors. While RPV offers reasonable value-focused exposure, cheaper alternatives like Vanguard's VTV (0.03% expense ratio) and Schwab's SCHD (0.06% expense ratio) may be more cost-effective for investors.
Centene (CNC) has surged 7.8% over the past month, reaching a new 52-week high of $69.63. The stock has gained 68.7% year-to-date, significantly outperforming its sector. The company has beaten earnings estimates for four consecutive quarters, with its latest report showing EPS of $2.51 versus consensus of $0.89. Trading at 14.2X forward EPS with a PEG ratio of 0.44, Centene carries a Zacks Rank #1 (Strong Buy) rating with an 'A' Value Score, suggesting potential for further gains in the near term.
With consumer sentiment hitting a 9-year low amid surging inflation and geopolitical tensions, investors are advised to consider defensive stocks from consumer staples and healthcare sectors. Four recommended stocks are Archer-Daniels-Midland (ADM), The Vita Coco Company (COCO), Amgen (AMGN), and Centene Corporation (CNC), all showing strong earnings growth and improved analyst estimates.
Common questions about price, predictions, long-term forecasts, technicals and research methodology.
CNC is currently shown at $66.01 in the latest stored market quote. The page is refreshed from the connected market-data pipeline.
A quantitative forecast is not currently available for CNC.
The 2026 long-term forecast section is included as a research framework. A numerical 2026 target is shown only after a dedicated long-horizon model has produced and validated it; the current 24H–90D model is not presented as a 2026 target.
The 2030 section tracks the inputs that a validated long-horizon model should use, including company growth, valuation, earnings, market regime and sector conditions. No unsupported price target is displayed.
The 2035, 2040 and 2050 sections are reserved for long-term model outputs. US Market AI does not invent numerical targets when validated long-horizon data is unavailable.
The page can display RSI, MACD, SMA 50, SMA 200, EMA 20, ATR, ADX, volatility, Bollinger levels, stochastic, support and resistance from stored daily price history.
Fundamental data is not currently populated for this stock, so the page does not estimate or fabricate missing values.
The latest ticker-linked news appears in the Market News section of this page. Stories are shown with source, publication date and sentiment when available.
There is not yet enough mature evaluation data on this page to claim a verified accuracy rate.
No. US Market AI provides research and model estimates for informational purposes. Forecasts can be wrong and should not be treated as personalized financial advice.
US Market AI combines quantitative signals and verified market data to support research. Forecasts are estimates, can be wrong, and are not financial advice.